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ABSTRAK 
 
Pengenalan:  Channa striatus (ikan haruan) telah terbukti dalam kajian-kajian terdahulu 
dapat mengurangkan keradangan dan kesakitan. Kajian ini bertujuan untuk menyelidik 
kesan anti radangnya terhadap proses radang dalam alahan hidung. 
Objektif: Untuk mengkaji kesan ekstrak ikan haruan ke atas tahap kandungan petunjuk 
keradangan alahan iaitu eosinofil dan interleukin-4 di dalam serum pesakit serta Markah 
Keseluruhan Simptom-simptom Hidung mereka.   
Rekabentuk kajian: Sebuah kajian rawak uji buta ganda dua, plasebo-kawalan, 
perbandingan klinikal dalam kumpulan selari selama enam minggu. Seramai empat puluh 
enam pesakit telah dibahagi secara rawak untuk menerima rawatan selama enam minggu 
menggunakan ekstrak ikan haruan ataupun plasebo. Pesakit diperiksa secara klinikal pada 
minggu permulaan, ke dua dan ke enam.  Darah diambil pada permulaan dan akhir rawatan 
bagi memeriksa tahap eosinophil dan interleukin-4 di dalam serum mereka.     
Keputusan: Kajian menunjukkan pengurangan dalam kadar yang signifikan bagi tahap 
eosinofil di dalam serum di kalangan kumpulan yang menerima rawatan ekstrak ikan 
haruan (p<0.05). Namun selepas analisa perbandingan dibuat di antara kedua-dua 
kumpulan rawatan, perbezaan puratanya menunjukkan hasil yang tidak signifikan secara 
xii 
 
statistik. Keputusan bagi tahap interleukin-4 di dalam serum juga menunjukkan hasil yang 
tidak signifikan secara statistik bagi kedua-dua kumpulan.  Perbezaan dalam pengurangan 
Markah Keseluruhan Simptom-Simptom Hidung di dalam kedua-dua kumpulan hanya 
signifikan bagi kumpulan pesakit yang mengalami simptom yang sederhana teruk dan teruk 
tetapi tidak bagi ringan. 
Kesimpulan: Walaupun ikan haruan hanya menunjukkan kesan modulasi imun yang 
sedikit di dalam ujian makmal, akan tetapi fungsinya sebagai rawatan tambahan dapat 
mengurangkan simptom alahan hidung secara signifikan bagi penghidap yang bersimptom 
sederhana teruk dan teruk. 
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ABSTRACT 
 
 
EFFECT OF CHANNA STRIATUS ON INFLAMMATORY MARKERS AS AN 
ADJUNCT TREATMENT IN ALLERGIC RHINITIS – A RANDOMIZED 
DOUBLE-BLINDED STUDY 
 
 
Introduction: Channa striatus (snakehead fish) have been shown to have anti-
inflammatory and anti-nociceptive properties. This study aimed to discover the effect of its 
anti-inflammatory property on the inflammatory process in allergic rhinitis. 
Objective(s): To determine the effect of Channa striatus extract on patients’ allergic 
rhinitis inflammatory markers, namely eosinophil and interleukin-4 level and their Total 
Nasal Symptoms Score. 
Methodology: A 6 weeks, randomized double-blinded placebo-controlled trial, parallel 
group comparative clinical study. Forty six allergic rhinitis patients were randomized to 
receive Channa striatus extract capsules or placebos for 6 weeks. Patients were assessed 
clinically at weeks 0, 2 and 6. Blood for serum eosinophil and interleukin-4 were taken at 
initial and final visit and the results were compared.    
xiv 
 
Results: The result showed significant decrement of serum eosinophil level in Channa 
striatus group (p<0.05) however the comparative analysis of the mean difference between 
two groups was not statistically significant. The result for interleukin-4 level showed no 
statistically significant changes in either group. The Total Nasal Symptoms Score reduction 
in both group are significant and comparative analysis of the mean difference between two 
groups was statistically significant for those with moderate and severe symptoms.    
Conclusion: Even though Channa striatus showed nonsignificant additional 
immunomodulation effects in laboratory analysis, however its role as an adjunct treatment 
in allergic rhinitis did show significant reduction in TNSS for patients with moderate and 
severe symptoms. 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Introduction 
Allergic rhinitis (AR) is a clinical condition where hypersensitivity of nasal mucosa occur 
on reaction toward foreign substances. The nasal mucosa inflammatory changes are 
mediated through IgE antibodies. It is a global problem and became a major concern in 
industrialized world due to its impact on patients’ quality of life. Allergic rhinitis sufferers 
might have poor productivity, lack of sleep and emotional disturbances. For children that 
suffer from allergic rhinitis, they might miss their school, lack of concentration during 
study or causing humiliation among their playmates. To control the symptoms is also costly 
let alone to cure it. 
 
It is estimated around half billion of the world population might suffer from allergic rhinitis 
(Bousquet et al, 2008). In Asia Pacific, a cross-national study on allergies showed that 37% 
of Malaysian population was having allergic rhinitis (Katelaris et al, 2011). In the state of 
Kelantan, its prevalence among shool children  age 12-14 years old was 38.2% (Quah et al, 
1997). The most common allergen is aeroallergen, especially house dust mites. Around 
73% percent of the studied population has sensitization toward two species of dust mites, 
Dermatophagoides pteronyssinus and Blomia tropicalis (Yeoh et al, 2003). 
 
Clinically, allergic rhinitis consists of four cardinal nasal symptoms, which are nasal 
obstruction, rhinorrhea, repeated sneezing and itchiness. The presence of at least two of 
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these symptoms for more than one hour on most days is suggestive of allergic rhinitis 
(Bousquet et al, 2008). According to Allergic Rhinitis and its Impact on Asthma (ARIA) 
Guidelines, allergic rhinitis can be divided and classified into mild intermittent, moderate-
severe intermittent, mild persistent and moderate-severe persistent (Bousquet et al, 2012). 
 
The best preventive control for allergic rhinitis is avoidance of allergen. The mainstay 
treatment for allergic rhinitis is medication. The treatment is given according to the severity 
of the symptoms. They consist of intranasal corticosteroids, oral anti-histamines, nasal 
decongestant and mast cell stabilizers. Immunotherapy should be considered for those with 
symptoms that are not well controlled with medication. 
 
For some patients, due to unsatisfactory response of their illness to these conventional 
medications, they tried to seek alternative treatment. The use of natural products has 
become an alternative treatment option for patients in the Western World. Clinicians have 
raised their concerns over the efficacy and possible side effects. Various herbs have been 
used in trials to treat patient with allergic rhinitis, such as Cinnamomum zeylanicum, 
Malphighia glabra, Bidens pilosa, Nigella sativa, Capsicum oleous and Shi Bi Lin (Ghazi-
Moghadam et al, 2012).  
 
In Malaysia, Channa striatus (snakehead fish) or locally known as haruan has been used 
traditionally in post-partum mother and post surgery. It is believed to make the recovery 
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faster and promote wound healing. Various studies were done locally and proved that this 
natural remedy indeed has the potentials to promote wound healing, anti-inflammatory and 
anti-nociceptive properties (Mat Jais, 2007). In our study, we tried to explore on the benefit 
and the anti-inflammatory property of the fish in treating allergic rhinitis. 
 
1.2 Pathophysiology of Allergic Rhinitis 
Allergic rhinitis is an inflammatory reaction comprises four phases – sensitization, early 
phase reaction, late phase reaction and systemic activation. 
 
1.2.1 Sensitization 
During initial phase of allergic rhinitis, antigens such as house dust mite, pollen and animal 
dander are deposited in the nasal mucosa. In the mucosa, these antigens are engulfed by 
antigen presenting cells (APCs) mainly Langerhans cells. Inside the APCs, polypeptide 
products of antigen are partially degraded into fragments. These fragments are then 
presented/expressed on the surface of APCs together with major histocompatibility 
complex to be recognized by naïve T-cells (CD4+). These T-cells then is activated, 
proliferated and differentiated into more specific Th2 cells. Once activated, Th2 cells 
secrete various cytokines such as IL-4, IL-5, IL-9 and IL-13. IL-4 and IL-13 (but with 
lower magnitude) are responsible for differentiation and growth of Th2 cells and B-cells 
activation. They help the B-cells to develop into plasma cells and induce their antibody 
class switching to IgE (Flint et al, 2010). Furthermore, IL-4 mediates the expression of 
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vascular cell adhesion molecule-1 (VCAM-1), promotes transmigration of eosinophil 
across endothelium and increase mucus secretion and more cytokine release from Th2 cells 
(Steinke & Borish, 2001).  Meanwhile, the secreted IL-5 is responsible for eosinophil 
proliferation, its chemotaxis and survival and the IL-9 induces mucus production and mast 
cells proliferation (Flint et al, 2010). The produced IgE then is bound to the cells that 
posses a specific receptor for Fc part of the IgE mainly mast cells. These well-armed mast 
cells now ready for the next phase of reaction (Fig.1).  
 
1.2.2 Early Phase Reaction 
Following exposure to the allergen, allergic inflammatory response takes place in the 
sensitized individuals. This occurs within minutes after the exposure. Allergen in the 
airway mucosa cross-links with IgE receptors on mast cells surface. Interaction between the 
allergen and immunoglobulin E causes subsequent release of mediators such as histamine. 
The histamine release causes mucus hypersecretion, an increase in vascular permeability 
and mucosal oedema (Fig.1). This may result in rhinorrhea, nasal congestion, sneezing and 
itching sensation in patient who suffer from allergic rhinitis (Flint et al, 2010). 
 
Beside histamine release, mast cell degranulation also lead to the release of other mediators 
and cytokines. From its membrane phospholipids, through the arachidonic acid pathways, 
leukotrienes and PGD2 are generated. Leukotrienes have their role in causing the increase 
vascular permeability and oedema of the nasal mucosa, eosinophils and neutrophils 
recruitment while prostaglandin D2 release is responsible for persistence nasal obstruction. 
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In addition to these events, various cytokines and chemokines transcription are induced and 
released. Among them are IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-11, IL-13, TNF-α, 
monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein 1 (MIP-1), 
granulocyte macrophage colony-stimulating factor (GMCSF) and regulated upon activation 
normal T expressed and secreted (RANTES) (Gleeson et al, 2008).  
 
This inflammation process that occurs in allergic rhinitis also has been linked to the 
excessive production of Th2 cytokines interleukin IL-4 and IL-5 relative to Th1 cytokine 
interferon INF-γ and IL-10. (De Wall et al, 1991; Fiorentino et al, 1991). These two types 
of Th1 cytokines  act as a regulatory or suppressor cytokine and has an important role in 
regulating the allergic immune response by facilitating T-cell tolerance and prevention of 
tissue inflammation.(Belinghausen et al, 2001; Takanashi et al, 1999). 
 
1.2.3 Late Phase Reaction 
After experiencing the early phase response, many patients show a late phase reaction  
characterized by cell adhesion molecule overexpression, release of inflammatory mediators 
with chemotactic activity and cytokine production that result in local tissue reaction 
(Naclerio et al, 1985; Skoner, 2001). It happens several hours after the exposure. At this 
phase, allergic sufferers might complain of nasal congestion, fatigue, malaise and 
irritability (Skoner, 2001).  
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Various effector cells involved for local tissue reaction in this phase. Mainly, they are 
eosinophils, basophils, mast cells, T lymphocytes, neutrophils and macrophages. Under the 
effect of chemotactic factors and modulating adhesion molecules that derived from 
endothelial and epithelial cells, these circulating effector cells adhere to the vascular 
endothelium and transmigrate to the reaction site. Cytokines levels also increase in this 
phase, especially IL-1, IL-4, IL-5, IL-6, IL-8, GM-CSF, soluble intercellular adhesion 
molecule-1 (ICAM-1) and TNF-α. (Flint et al, 2010).  
 
Eosinophils play an important role in this stage. Tissue migration and activation of this 
effector cells are mediated and regulated by IL-5, GM-CSF,  leukotriene B4  (LTB4), 
ICAM, vascular cellular adhesion molecule (VCAM) and several other chemokines such as 
RANTES and eotaxin (Gleeson et al, 2008).  
 
Once eosinophils mature in nasal mucosa, they secrete major basic protein (MBP), 
eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN), peroxidase and 
beta glucoronidase. They also have the ability to produce and release cytokines to cause 
further allergic inflammatory reaction. Among them are IL-3, IL-5, GM-CSF, cysteinyl 
leukotrienes, prostaglandin E1 and transforming growth factor (TGF) β1. All of these 
causing increase vascular permeability, mucus secretion and further recruitment of effector 
cells. 
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1.2.4    Systemic Activation 
In final phase, systemic activation of immune processes can be observed in patient with 
allergic rhinitis. A stable basophilia is one of the effects of systemic activation. Circulating 
basophils could increase up to 2 folds during allergy season (Bochner, 2000). Since they 
are the only leukocytes that contain histamine in the blood stream, individuals with allergic 
rhinitis would have a larger source of histamine to be released during allergic response. 
Studies also have shown that circulating basophils are the main source for IL-4 and IL-13 
production in response to specific antigen (Bochner, 2000).  
 
There would also be an increased eosinophils numbers in the bone marrow, blood stream 
and tissues. One of the specific eosinophil growth factor, IL-5 which is secreted by Th2-
cell is responsible for the increase production of eosinophils in bone marrow. From the 
bone marrow, eosinophils travel in circulation to reach the site of allergic inflammation and 
responsible for inflammatory reaction as mentioned. It has been observed that on initial 
event of allergen inhalation there was a decrease in the level of eosinophil in circulation 
followed by a rebound increase. The assumption for the initial decrement is the migration 
of eosinophils from the circulation to the site of inflammation and followed by increase 
production and release of eosinophils from bone marow under the influence of IL-5 
(Bochner 2000).  
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Figure 1: Phases of allergic reaction in the nose (Adapted from Gleeson M et al. 2008). 
 
1.3 Eosinophil Count in Allergic Rhinitis 
In allergic rhinitis, the skin prick test and specific IgE give the best predictive value.  
However serum inflammatory markers such as total serum IgE, eosinophil cationic protein 
and eosinophil percentage still can be the strong predictor of allergic rhinitis as reported by 
Jung and colleagues (Jung et al, 2011). They concluded the cut-off values in serum sample 
for these markers as followed - 98.7 IU/ml for IgE, 24.7µg/ml for eosinophil cationic 
protein (ECP) and 4.0% for eosinophils count. The specificity of eosinophils count for 
allergic rhinitis that was concluded in the study is 72%. 
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Eosinophil count is related to severity of allergic rhinitis. To compare the effectiveness of 
alternative medicines and herbs in treating allergic rhinitis, various studies used eosinophil 
counts as a parameter (Chen et al, 2009; Kalus et al, 2003; Xiao et al, 2006; Yang et al, 
2010). 
 
However it is uncommon for eosinophil count to exceed 1500/ul in allergic rhinitis 
(Nutman, 2007). High eosinophil level in serum or eosinophilia also can be observed in 
other illnesses such as parasitic infection, atopic dermatitis, malignancy, fungal infection, 
drug intake and certain immunologic and endocrine disorders. Eosinophil level in the blood 
stream also has its normal physiological fluctuation with the highest level in peripheral 
blood in the morning (Nutman, 2007).     
 
1.4 Interleukin-4 in Allergic Rhinitis 
In the individual with allergic rhinitis, interleukin-4 (IL-4) is increase in serum and nasal 
lavage. IL-4 plays a central role in the IgE synthesis system, the development of Th-2-like 
cells, and co-ordination as well as the persistence of airway inflammatory process in 
allergic disorders. Treatment with anti-histamine and immunotherapy will decrease it level. 
 
The percentage decrease in IL-4 is correlated significantly with the percentage decrease in 
specific IgE antibodies following long-term immunotherapy (Ohashi et al, 1996). In a 
study, to observe the effect of antihistamine type-2 on serum interferon gamma, IL-4 and 
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IL-12 in allergic rhinitis patients, it has been shown that immunotherapy and H2 receptor 
antagonist lead to improvement in symptoms with the decrease of IgE antibodies and IL-4 
in blood (Testa et al, 2001). While in another observation following usage of a 
conventional anti-histamine, cetrizine, an increase of IFN-γ/IL-4 ratio was observed (Uğuz 
et al, 2005). 
 
In alternative treatment for allergic rhinitis, Li et al used allergic rhinitis models in rats to 
investigate the effect of garlicin on serum level of INF-gamma and IL-4. They had shown a 
significant decrease in serum level IL-4 together with increment of serum INF- γ after 
garlicin administration (Li et al, 2008). 
 
1.5 Total Nasal Symptoms Score 
Total Nasal Symptoms Score is the sum of all four nasal symptoms score. The score is 
based on four main nasal symptoms of allergic rhinitis which are nasal obstruction, nasal 
itchiness, rhinorrhea and nasal itching. It is measured on four point rating scale for each 
symptom. Until now, there was no single universally accepted scale to rate allergic rhinitis 
symptoms, however this four point rating scale is generally accepted. According to 
European Medicines Agency Guideline and U.S Food and Drug Administration for clinical 
development program of allergic rhinitis, the scale that were used are as follows (Himmel, 
2000) : 
• 0 = absent of symptoms (no sign/symptoms evident) 
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• 1 = mild symptoms (sign/symptoms clearly present, but minimal awareness, easily 
tolerated) 
• 2 = moderate symptoms (definite awareness of sign/symptom that is bothersome but 
tolerable) 
• 3 = severe symptoms (sign/symptom that is hard to tolerate; causes interference 
with activities of daily living and/or sleeping) 
 
1.6 Channa striatus  
Snakehead fish (Channa striatus, Channidae), belongs to the family Channidae. It exists as 
a wild freshwater, carnivorous fish commonly found in shallow water. It is widely 
distributed in Malaysia, South-East Asia countries, Taiwan, India and Indochina region 
(Mohsin & Ambak, 1983). It is native to Malaysia and has been proved it existed in our 
region since 600,000 years ago (Mat Jais, 2007). 
 
Traditionally, it has been used for generations in post-partum mother and post-trauma 
patient. Among Malay, Chinese and Indian community, it is believed that this fish is a great 
natural remedy. It has been consumed as a protein source in their diet or prepared 
specifically for harnessing their healing potential. In some region, it is not a weird scene 
when the living fish is swallowed and was claimed that it gives a miraculous effect to their 
illness (BBC, 2003). 
 
12 
 
Because of this vast potential, since the past twenty years researchers have done extensive 
studies and proved that this fish in deed has great medicinal properties. It contains 17 
essential amino acids and has high lipid content (Zakaria et al, 2007). The amino acids that 
present in high amount in this fish is glutamic acid, aspartic acid and lysine (Zuraini et al, 
2005). The lipid contains mostly various kinds of essential fatty acids. It contains rich 
amount of docosahexaenoic acid (DHA), oleic acid, stearic acid and arachidonic acid 
(Zuraini et al, 2005). These essential fatty acids that present in the fish have a role in 
modulating prostaglandin metabolism hence the inflammation process (Simopoulos, 2002).  
 
Apart from its antinociceptive properties (Mat Jais et al, 1997)  and ability to promote 
wound healing (Baie & Sheikh, 2000), a study by Zakaria 2008 showed that Channa 
striatus fillet aqueous and lipid-based extracts of the fish have significant antiinflammatory 
activity. They performed experiment on rats using the haruan extract and gave evidence of 
its antiinflammatory activity. In his study, antiinflammatory and antipyretic activities were 
assessed using the carrageenan-induced paw edema and brewer's yeast-induced pyrexia 
tests. The aqueous and lipid-based extracts were found to show significant 
antiinflammatory activity (Zakaria, et al, 2008). 
 
Channa striatus extract usage also shown a reduction in inflammation of osteroarthritic 
rabbits joint. In this preliminary study, inflammation of arthritic joints was reduced in joints 
treated with Channa striatus (Michelle et al, 2004). 
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Anti-inflammatory action of C.striatus extract could be explained by the high concentration 
of its fatty acids content. Stearic acid and oleic acid in the extract could suppress 
inflammatory responses by attenuating the polymorphonuclear leucocytes activity (Zakaria 
et al, 2007). The presence of high proportion of monosaturated fatty acid such as oleic acid 
in plasma could lead to decrement of arachidonic acid proportion in plasma. As we know 
from arachidonic acid metabolism (Fig. 2), inhibition of its cascade will result in reduction 
of eicosanoids formation hence decrease inflammation (Croker et al, 2002).  
 
Another possible explanation for its anti-inflammatory action is the role of its DHA 
content. DHA could alter the arachidonic acid metabolism and inhibits its proinflammatory 
lipid mediator’s formation (Mat Jais, 2007). 
 
14 
 
 
Figure 2: Biosynthesis of leukotrienes, prostaglandin and thromboxane from 
arachidonic acid (Adapted from Harvey R, Ferrier D., 2011. Lippincott's Illustrated 
Reviews: Biochemistry, Fifth Edition.)   
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1.7 Essential Fatty Acids and its role in Allergic Rhinitis 
Since industrialization, the human diet has changed. People tend to eat more processed food 
that contains unbalanced composition of various fat. Studies in Europe suggested that their 
modern diet contains more polyunsaturated fatty acids which could be precursor to 
arachidonic acid. Excessive formation of arachidonic acid could lead into more formation 
of IgE in the body (Dunder et al, 2001).  By taking more balanced diets that contains n-3 
fatty acids, it could decrease the risk of allergic rhinitis and atopic diseases (Dunder et al, 
2001, Hoff et al, 2005). N-3 fatty acids or commonly known as omega-3 fatty acids that 
involved in our physiology are alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA). The main source of ALA in human is from plant origin. 
It is known that human body is not efficient in converting the ALA into EPA and DHA 
(Brenna, 2005). Hence, most of EPA and DHA that we need have to be derived from our 
diet. Among animals that are efficient to produce EPA and DHA are fish (Kris-Etherton et 
al, 2003). 
 
In allergic rhinitis, leukotriene B4 (LTB4), one of the proinflammatory lipoxygenase 
products plays an important role in its pathophysiology. Its level in the blood is elevated in 
various allergic diseases. This leukotriene is produced by leukocytes from the membrane 
phospolipid arachidonic acid (Ohnishi et al, 2008). LTB4 action in allergic rhinitis is related 
to its role in inducing IgE production by normal peripheral blood mononuclear cells and E-
cells (PBMC partially depleted of T cells). However, it cannot react directly on the PBMC 
or E-cells alone. Its reaction depends on availability of Interleukin-4 (Yamaoko et al, 
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1994). LTB4 also play its role in allergic rhinitis by becoming a chemo-attractant to the 
eosinophils (Kikuchi et al, 1998). 
 
Studies showed that DHA and EPA that present in fish and fish oil has modulating effect 
on the eosinophil chemotactic and chemokinetic response to LTB4 (Kikuchi et al, 1998). In 
human body, the ingested DHA and EPA will be integrated into neutrophil and monocytes 
cell membranes and change its arachidonic acid make-up, hence inhibit the LTB4 formation 
from arachidonic acid (Ohnishi et al, 2008). 
  
1.8 Rationale/Justification of Study 
In today’s modern world, around the globe more and more people tried to live as natural as 
possible. It gives alternative and complementary medicine a place in this modern world. 
Traditional medications resurfaced with more scientific evidences. As clinicians in a 
tropical country that has abundant natural resources with medicinal properties that can be 
exploited and researched further, we took this opportunity to explore the therapeutic 
potential that presents inside Channa striatus and its extract. 
 
Through previous studies, we already knew that this fish has high protein and fatty acids 
content. Presence of various essential amino acids and essential fatty acids  have made this 
fish capable to promote wound healing, modulating anti-inflammatory action and anti-
nociceptive in our body. 
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Although various studies were done to investigate its anti-inflammatory action, there was 
no research conducted to study its anti-inflammatory potential in allergic rhinitis patients. 
We hope with the completion of this study, we can know its immune-modulatory effect or 
at least, its capability in relieving the symptoms of allergic rhinitis. 
  
Our hope, this study will open a new path for further research in alternative therapy for 
allergic rhinitis sufferers. The success of this study indirectly will promote our local 
product to be used as an adjunct treatment, to be used as adjunct with the conventional 
treatment, and finally boosting our agricultural sector. Further research could be done to 
determine its optimal dosage in the future and its interaction with other dietary intake. 
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CHAPTER 2: OBJECTIVES 
 
 
2.1 General Objective: 
To determine the effect of Channa striatus extract as an adjunct treatment on the serum 
level of allergy inflammatory markers in allergic rhinitis patient.  
 
2.2 Specific Objectives: 
1. To determine the mean difference of serum eosinophil count for Channa striatus and  
placebo group before and after treatment. 
2. To compare the mean difference of serum eosinophil count for Channa striatus and 
placebo group. 
3. To determine the mean difference of serum Interleukin-4 between Channa striatus and 
placebo group before and after treatment. 
4. To compare the mean difference of serum Interleukin-4 between Channa striatus and 
placebo group. 
5. To observe the effect of Channa striatus extract as an adjunct treatment on patients’ total 
nasal symptom scores. 
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CHAPTER 3: MATERIALS AND METHODOLOGY 
 
3.1 Study Question 
 1. Does the Channa striatus extract intake will result in decrement of allergy 
inflammatory markers in patients with allergic rhinitis? 
 
               2. Does the Channa striatus extract will lead to decrease of total nasal symptoms 
score? 
 
3.2 Study Hypothesis 
Null hypothesis – There is no difference outcome in allergy inflammatory markers level 
between the Channa striatus extract group and the control group. 
Alternative hypothesis – There is a significant decrement in serum allergy inflammatory 
markers in Channa striatus group compared to the control group.  
 
3.3  Study Design 
This is a double blind randomized controlled trial study of Channa striatus extract versus 
placebo in selected patients with allergic rhinitis. 
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3.4  Population and Sample 
3.4.1 Subject Selection  
The sampling population was recruited from patients who attended Otorhinolaryngology- 
Head and Neck Surgery (ORL-HNS) clinic at Universiti Sains Malaysia Hospital, Kubang 
Kerian, Kelantan beginning from February 2014 till June 2014.  
 
3.4.2  Sampling Method 
Subjects were selected through convenience sampling. Patients who attended the ORL-
HNS clinic and met the inclusion and exclusion criteria as mentioned below were included 
in the study. 
 
3.5 Inclusion and Exclusion Criteria 
3.5.1 Inclusion Criteria 
            1.  Patients between 18-50 years old as more of older population suffering from  
non-allergic rhinitis. 
2.  Patients diagnosed as allergic rhinitis based on clinical examination. 
 3.  Patients with skin prick test positive for allergy. 
 4.  Patients with intranasal corticosteroid as main treatment. 
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3.5.2  Exclusion Criteria 
 1. Pregnancy and nursing females as it may affect the baby. 
 2. Patients with significant medical illness that on multiple medications. 
 3. Patients with severe atopic dermatitis, asthma and history of anaphylaxis. 
 4. Patient with concurrent rhinosinusitis or other nasal pathology. 
 5. Patients with history of nasal surgery. 
 6. Patients on systemic corticosteroid therapy. 
 7. Patients treated with systemic adrenergic drug. 
 8. Patients who have history of allergy to Channa striatus or its related product. 
 9. Patients who already took haruan as their regular diet.  
 
3.6  Sample Size Calculation 
The sample size was calculated using two means formula, based on previous study by Maiti 
et al, (2010).  
 
We planned a study of a continuous response variable from independent control and 
experimental subjects with 1 control(s) per experimental subject.  In a previous study the 
response within each subject group was normally distributed with standard deviation 
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205.66.  If the true difference in the experimental and control means is 166.9, we will need 
to study 23 experimental subjects and 23 control subjects to be able to reject the null 
hypothesis that the population means of the experimental and control groups are equal with 
probability (power) 0.8.   The Type I error probability associated with this test of this null 
hypothesis is 0.05. 
                  2σ²    
   n   =     ---------  ( Zα  +  Zβ ) ² 
                   Δ²  
 
                  2 (205.66)²    
   n   =     ---------  ( 1.96  + 0.84  ) ² 
                   166.90²  
 
 
             n =  23.3  
 
Hence, 23 subjects for each group included twenty percent calculated drop-out, with total 
of 56 subjects as the sample size. 
 
3.7  Study Protocol and Ethical Consideration 
3.7.1 Study Protocol 
The study protocol was approved by Research Ethics Comittee (Human), Universiti Sains 
Malaysia, Kubang Kerian, Kelantan [Ref. no: USM/JEPeM/273.3(9)]. Patients who 
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attended ORL-HNS clinic and fulfilled the inclusion and exclusion criteria were recruited 
for this study. After a detailed explanation regarding the diagnosis and proposed treatment, 
patients were allowed to make decision either want to continue their conventional 
medication or volunteer to join the study and using the alternative treatment as an adjunct 
medication. Risk and benefit of the studied medication explained. An informed written 
consent was obtained from each patient who participated in this study. Patients underwent 
routine history taking, clinical assessment and skin prick test for allergic rhinitis. After 
randomization, they were divided into study and control group. Blood samples for FBC, 
RFT, LFT, differential count for eosinophil and IL-4 were taken at initial visit and after 6 
weeks of treatment. At 2 weeks of treatment, a clinical assessment was made to monitor 
patient compliance or any adverse effects that may occur. Collected data then analyzed 
using computer software. 
 
3.7.2 Ethical Consideration 
After thorough explanation, the well informed patients were asked to sign the written 
consent. A copy of the written and signed consent was given to each participant. All 
participants in this study involved voluntarily and they were permitted to withdraw from 
the study at any moment they considered necessary. 
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3.8 Methods and Instruments 
3.8.1 Methods 
Patients who attended the clinic with allergic rhinitis symptoms were seen by investigator 
and diagnosis were made based on history and physical examination.  Informed consents 
were taken from the patients. Those who agreed to participate in the study were subjected 
to skin prick test. 
 
Subject who met the criteria of allergic rhinitis and had positive skin prick test was 
included in the study. Those who was on oral anti-histamine was asked to stop taking their 
medication at least two weeks prior to participation in this study as a wash-out period while 
still continuing using intranasal corticosteroid. For those who has consumed haruan 
regularly or taking traditional medication, they were asked to withhold their intake 1 month 
prior to the study. 
 
Patients were subjected to 2 follow-ups at week 2 and week 6 after the treatment initiated.  
They began with answering questionnaire related to their symptoms and were given the 
trial drug. The questionnaire was intended to assess their total nasal symptoms score. Until 
now, there were no single universal symptoms score for allergic rhinitis accepted as  a 
standard.  However the measurement based on 4 point rating scale is widely accepted. The 
nasal symptoms that were assessed are nasal obsctruction, nasal discharge/rhinorrhea, 
